Clarity Locks in 650,000 Dose US Manufacturing Capacity Ahead of FDA Decision
Clarity Pharmaceuticals (ASX: CU6) has signed a Commercial Manufacturing Agreement with Nucleus RadioPharma for its lead diagnostic candidate, 64Cu-SAR-bisPSMA, securing combined capacity of approximately 650,000 patient doses per year across two US facilities. The agreement, effective 14 April 2026, positions the clinical-stage radiopharmaceutical company for rapid commercial scale-up ahead of anticipated US Food and Drug Administration (FDA) approval.
Clarity Pharmaceuticals secures US commercial manufacturing deal for lead diagnostic candidate
The agreement with Nucleus RadioPharma covers two strategically positioned US facilities designed to service all 50 states plus select international markets including Europe. The Rochester, Minnesota site, already operational, can manufacture approximately 50,000 patient doses annually. A second facility in Spring House, Pennsylvania, planned to open in 2028, will add up to 600,000 doses per year from its 47,000 square foot production site.
This Commercial Manufacturing Agreement builds on an existing partnership established in November 2024, when Clarity signed a Master Services Agreement and 67Cu-SAR-bisPSMA Clinical Supply Agreement with Nucleus RadioPharma. The deepening relationship demonstrates increasing commercial alignment as Clarity advances 64Cu-SAR-bisPSMA through Phase III registrational trials, AMPLIFY (NCT06970847) and CLARIFY (NCT06056830), ahead of New Drug Application (NDA) submission.
Dr Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals, stated: “Clarity is building a strong foundation with its supply and manufacturing strategy to support a large-scale commercial rollout of 64Cu-SAR-bisPSMA from day one, with capability to supply not only the entire existing PSMA PET market, but a larger pool of patients that could benefit from our optimised product.”
For biotech investors, securing large-scale manufacturing infrastructure before regulatory approval signals management confidence in clinical success and execution on commercialisation strategy, a key differentiator for companies approaching pivotal data readouts.
When big ASX news breaks, our subscribers know first
What is a commercial manufacturing agreement and why does it matter for biotech investors?
Clinical-stage biotechnology companies must secure manufacturing capacity well ahead of potential regulatory approval to avoid supply bottlenecks at commercial launch. This strategic timing becomes particularly critical in radiopharmaceuticals, where radioactive decay imposes unique logistics constraints that standard pharmaceutical distribution networks cannot accommodate.
Radiopharmaceuticals lose potency due to radioactive half-life, the time required for half of the radioactive atoms to decay. Copper-64, the isotope used in Clarity’s 64Cu-SAR-bisPSMA diagnostic, has a 12.7-hour half-life, significantly longer than competing isotopes such as gallium-68 (68 minutes) or fluorine-18 (110 minutes). This extended half-life enables broader geographic distribution from centralised manufacturing facilities rather than requiring on-site production at every imaging centre.
Manufacturing agreements therefore de-risk the commercial pathway by confirming that adequate production capacity, distribution logistics, and supply chain infrastructure will be operational if clinical trials succeed and regulatory approval is granted. For investors evaluating clinical-stage companies, these agreements provide tangible evidence of commercial preparation beyond trial design and patient enrolment updates.
US manufacturing footprint designed for nationwide coverage
Clarity’s two-facility strategy positions production sites to serve distinct geographic regions whilst creating supply redundancy. The Rochester facility in Minnesota provides midwest coverage, whilst the larger Spring House site in Pennsylvania will anchor northeast distribution when operational in 2028.
| Facility | Location | Capacity | Status |
|---|---|---|---|
| Rochester | Minnesota | ~50,000 doses/year | Operational |
| Spring House | Pennsylvania | Up to 600,000 doses/year | Opening 2028 |
The combined annual capacity of approximately 650,000 doses would position Clarity to capture significant market share across all major US regions from day one of commercial launch, assuming successful Phase III trial outcomes and FDA approval. Nucleus RadioPharma confirmed the facilities will distribute to all 50 US states and select international sites.
Dr Stephen Hahn, Chief Executive Officer of Nucleus RadioPharma, commented: “64Cu-SAR-bisPSMA is now quickly approaching its market launch, and with recently released data highlighting its detection benefits in comparison to standard of care PSMA PET, we could not be more excited about being part of the change in shaping the future of prostate cancer diagnostics.”
The tiered geographic approach creates operational flexibility to meet regional demand fluctuations whilst reducing single-point-of-failure risk in the manufacturing supply chain.
Expanding copper-64 supply network reduces single-source risk
Beyond drug product manufacturing, Clarity has established multiple agreements across the copper-64 supply chain to secure isotope availability at commercial scale. The company’s broader manufacturing ecosystem now includes:
- Nucleus RadioPharma (this agreement) for drug product manufacturing
- SpectronRx for copper-64 supply and drug product manufacturing
- Nusano for copper-64 supply
- Theragenics for copper-64 supply
Clarity already has a separate 64Cu-SAR-bisPSMA commercial manufacturing agreement in place with SpectronRx, creating parallel production pathways across distinct US geographies. Dr Taylor described this as a “tiered approach with regional distribution” designed to support commercial-scale demand with secure and abundant supply.
Multiple manufacturing and supply agreements reduce execution risk by preventing over-reliance on any single production facility or isotope supplier. This network structure provides operational flexibility to redirect production if individual sites experience capacity constraints, regulatory issues, or technical disruptions, a material consideration for radiopharmaceutical products where supply interruptions directly impact patient care delivery.
Phase III trials to determine commercial pathway
Commercial sales of 64Cu-SAR-bisPSMA remain contingent on successful completion of two ongoing Phase III registrational trials, NDA submission, and FDA approval. The AMPLIFY trial (NCT06970847) and CLARIFY trial (NCT06056830) are designed to demonstrate the diagnostic’s clinical utility in prostate cancer detection and staging compared to current standard-of-care PSMA PET imaging.
Recent data referenced by Nucleus RadioPharma management suggests 64Cu-SAR-bisPSMA may offer detection advantages over existing PSMA PET technologies, though the product’s safety and efficacy have not yet been assessed by the FDA or Therapeutic Goods Administration (TGA).
Dr Geoffrey Johnson, Chief Scientific Officer of Nucleus RadioPharma
“64Cu-SAR-bisPSMA… is capable of visualising tiny prostate cancer lesions that the current standard of care PSMA PET fails to detect. Earlier cancer detection and better cancer staging directly affects patient management and treatment outcomes.”
The manufacturing agreement positions Clarity for rapid commercial scale-up if Phase III data supports regulatory approval, but investors should note that 64Cu-SAR-bisPSMA is an unregistered product with no guarantee of commercial availability. Trial outcomes and regulatory decisions represent the primary determinants of whether the manufacturing infrastructure secured through this agreement will generate revenue.
The next major ASX story will hit our subscribers first
Strategic outlook and next steps
With manufacturing infrastructure now secured across two US facilities and copper-64 supply agreements in place with multiple providers, Clarity has established the operational foundation for commercial launch pending successful clinical and regulatory milestones. The company’s supply and manufacturing strategy positions it to serve the existing PSMA PET market whilst potentially expanding the addressable patient population if clinical data demonstrates detection advantages.
Copper-64’s extended half-life relative to competing isotopes enables flexible delivery models from centralised manufacturing sites, reducing the capital intensity and complexity of commercial distribution compared to shorter-lived radiopharmaceuticals requiring localised production networks.
Dr Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals
“The half-life of copper-64 gives us the freedom to deliver a number of models in order to meet the future demand for our products.”
For investors, the focus now shifts to Phase III trial readouts as the next major value catalyst. Manufacturing agreements de-risk commercial execution but do not eliminate clinical or regulatory uncertainty. The timeline for AMPLIFY and CLARIFY data releases, subsequent NDA submission, and FDA review will determine when, and whether, the production capacity secured through this agreement translates into commercial revenue.
The Commercial Manufacturing Agreement includes cancellation and extension provisions aligned with industry standard rates, providing operational flexibility as clinical timelines evolve. With the Rochester facility already operational and Spring House planned for 2028, Clarity has staged its manufacturing scale-up to align with anticipated commercial demand progression following potential regulatory approval.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to receive real-time alerts the moment market-moving announcements hit the ASX across Healthcare, Tech, Finance and more.